X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ATYR1923 (efzofitimod) is a tRNA synthetase-derived therapy based on a naturally occurring, lung-enriched, splice variant of histidyl-tRNA synthetase (HARS). It is being evaluated for the treatment of pulmonary sarcoidosis.
Lead Product(s): Efzofitimod
Therapeutic Area: Immunology Product Name: ATYR1923
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
Efzofitimod is a first-in-class biologic immunomodulator, under phase 2 clinical trials for systemic sclerosis-related interstitial lung disease. It selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve inflammation without immune suppression.
Lead Product(s): Efzofitimod
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ATYR1923
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
ATYR1923 (efzofitimod) is a potential first-in-class, works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent Systemic Sclerosis.
Lead Product(s): Efzofitimod
Therapeutic Area: Immunology Product Name: ATYR1923
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
ATYR0101 binds to human fibroblasts and extracellular matrix deposited by fibroblasts via novel binding of LTBP1. LTBP1 is an extracellular matrix protein and key regulator of TGF-β, a central player in the pathogenesis of fibrotic diseases.
Lead Product(s): ATYR0101
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ATYR0101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
ATYR1923 (efzofitimod) is a potential first-in-class, works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis.
Lead Product(s): Efzofitimod
Therapeutic Area: Immunology Product Name: ATYR1923
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
aTyr intends to use the net proceeds for general corporate purposes, including the ongoing development of ATYR1923 (efzofitimod) and the expansion of its clinical development program to include a planned Phase 2 study of efzofitimod in patients with systemic sclerosis.
Lead Product(s): Efzofitimod
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ATYR1923
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: RBC Capital Markets
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 09, 2023
Details:
ATYR1923 (efzofitimod) is a potential first-in-class, works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis.
Lead Product(s): Efzofitimod
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ATYR1923
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2023
Details:
ATYR1923 (efzofitimod) is a potential first-in-class, works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis.
Lead Product(s): Efzofitimod,Pirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ATYR1923
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
ATYR1923 (efzofitimod), a fusion protein comprised of the immunomodulatory domain of histidyl-tRNA synthetase fused to the FC region of a human antibody, is a selective modulator of neuropilin-2 that downregulates innate and adaptive immune response in inflammatory disease.
Lead Product(s): Efzofitimod
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ATYR1923
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
Efzofitimod (ATYR1923) is a first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory diseases states via selective modulation of neuropilin-2 (NRP2).
Lead Product(s): Efzofitimod
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ATYR1923
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
